Background: Vitamin D is a pro-hormone that plays an essential role in the vasculature and in kidney function. Aims: To review the extra-skeletal effects of vitamin D on blood pressure, endothelial and renal function with emphasis on recent findings in postmenopausal women. Methods: Included in this review was a PubMed database search for English language articles through March 2013. This review discussed the physiology and definition of vitamin D deficiency, the recent evidence for the role vitamin D in blood pressure, vascular and renal function. Results: Experimental and epidemiological data suggest that vitamin D plays an important role in the vasculature and in kidney function. Low vitamin D concentrations appear to significantly associate with hypertension, endothelial and renal dysfunction. However, the results of clinical trials have generally been mixed. Studies specifically conducted among postmenopausal women are limited and findings are still inconsistent. Conclusions: Definitive studies are warranted to elucidate the effects of vitamin D supplementation on vascular and renal function and a more detailed work is needed to outline the route, duration and optimal dose of supplementation. It is premature to recommend vitamin D as a therapeutic option in the improvement of vascular and renal function at the current stage.
References
[1]
Perez-Lopez, F.R.; Chedraui, P.; Fernandez-Alonso, A.M. Vitamin d and aging: Beyond calcium and bone metabolism. Maturitas 2011, 69, 27–36, doi:10.1016/j.maturitas.2011.02.014.
[2]
Duque, G.; El Abdaimi, K.; Macoritto, M.; Miller, M.M.; Kremer, R. Estrogens (e2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: Changes with aging and hormone deprivation. Biochem. Biophys. Res. Commun. 2002, 299, 446–454, doi:10.1016/S0006-291X(02)02657-8.
[3]
Mithal, A.; Wahl, D.A.; Bonjour, J.P.; Burckhardt, P.; Dawson-Hughes, B.; Eisman, J.A.; El-Hajj Fuleihan, G.; Josse, R.G.; Lips, P.; Morales-Torres, J. Global vitamin D status and determinants of hypovitaminosis d. Osteoporos. Int. 2009, 20, 1807–1820, doi:10.1007/s00198-009-0954-6.
[4]
Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266–281, doi:10.1056/NEJMra070553.
[5]
Sai, A.J.; Walters, R.W.; Fang, X.; Gallagher, J.C. Relationship between vitamin D, parathyroid hormone, and bone health. J. Clin. Endocrinol. Metab. 2011, 96, E436–E446, doi:10.1210/jc.2010-1886.
[6]
Howe, W.R.; Dellavalle, R. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266–281, doi:10.1056/NEJMra070553.
[7]
Gaugris, S.; Heaney, R.P.; Boonen, S.; Kurth, H.; Bentkover, J.D.; Sen, S.S. Vitamin D inadequacy among post-menopausal women: A systematic review. Q. J. Med. 2005, 98, 667–676, doi:10.1093/qjmed/hci096.
[8]
Wat, W.Z.; Leung, J.Y.; Tam, S.; Kung, A.W. Prevalence and impact of vitamin D insufficiency in southern chinese adults. Ann. Nutr. Metab. 2007, 51, 59–64, doi:10.1159/000100822.
[9]
Lim, S.K.; Kung, A.W.; Sompongse, S.; Soontrapa, S.; Tsai, K.S. Vitamin D inadequacy in postmenopausal women in Eastern Asia. Curr. Med. Res. Opin. 2008, 24, 99–106, doi:10.1185/030079908X253429.
[10]
Kung, A.W.; Lee, K.K. Knowledge of vitamin d and perceptions and attitudes toward sunlight among chinese middle-aged and elderly women: A population survey in hong kong. BMC Public Health 2006, 6, 226, doi:10.1186/1471-2458-6-226.
[11]
Lips, P.; Duong, T.; Oleksik, A.; Black, D.; Cummings, S.; Cox, D.; Nickelsen, T. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J. Clin. Endocrinol. Metab. 2001, 86, 1212–1221, doi:10.1210/jc.86.3.1212.
[12]
Baz-Hecht, M.; Goldfine, A.B. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17, 113–119, doi:10.1097/MED.0b013e3283372859.
[13]
Dawson-Hughes, B.; Mithal, A.; Bonjour, J.P.; Boonen, S.; Burckhardt, P.; Fuleihan, G.E.; Josse, R.G.; Lips, P.; Morales-Torres, J.; Yoshimura, N. Iof position statement: Vitamin D recommendations for older adults. Osteoporos. Int. 2010, 21, 1151–1154.
[14]
Ross, A.C.; Manson, J.E.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.; Gallagher, J.C.; Gallo, R.L.; Jones, G.; et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: What clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96, 53–58, doi:10.1210/jc.2010-2704.
[15]
Dawson-Hughes, B.; Heaney, R.P.; Holick, M.F.; Lips, P.; Meunier, P.J.; Vieth, R. Estimates of optimal vitamin D status. Osteoporos. Int. 2005, 16, 713–716.
[16]
Carter, G.D.; Carter, R.; Jones, J.; Berry, J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin. Chem. 2004, 50, 2195–2197.
[17]
Zerwekh, J.E. Blood biomarkers of vitamin d status. Am. J. Clin. Nutr. 2008, 87, 1087S–1091S.
[18]
Calvo, M.S.; Whiting, S.J.; Barton, C.N. Vitamin D fortification in the united states and canada: Current status and data needs. Am. J. Clin. Nutr. 2004, 80, 1710S–1716S.
[19]
Dusso, A.S.; Brown, A.J.; Slatopolsky, E. Vitamin D. Am. J. Physiol. Ren. Physiol. 2005, 289, F8–F28, doi:10.1152/ajprenal.00336.2004.
[20]
Holick, M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80, 1678S–1688S.
[21]
Wolpowitz, D.; Gilchrest, B.A. The vitamin D questions: How much do you need and how should you get it? J. Am. Acad. Dermatol. 2006, 54, 301–317, doi:10.1016/j.jaad.2005.11.1057.
[22]
Chel, V.; Wijnhoven, H.A.; Smit, J.H.; Ooms, M.; Lips, P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos. Int. 2008, 19, 663–671.
[23]
Wu, F.; Staykova, T.; Horne, A.; Clearwater, J.; Ames, R.; Mason, B.; Orr-Walker, B.; Gamble, G.; Scott, M.; Reid, I. Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. N. Z. Med. J. 2003, 116, U536.
[24]
DeLuca, H.F. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 2004, 80, 1689S–1696S.
[25]
Heaney, R.P. The vitamin D requirement in health and disease. J. Steroid Biochem. Mol. Biol. 2005, 97, 13–19.
[26]
Merke, J.; Milde, P.; Lewicka, S.; Hugel, U.; Klaus, G.; Mangelsdorf, D.J.; Haussler, M.R.; Rauterberg, E.W.; Ritz, E. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J. Clin. Investig. 1989, 83, 1903–1915, doi:10.1172/JCI114097.
[27]
Merke, J.; Hofmann, W.; Goldschmidt, D.; Ritz, E. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif. Tissue Int. 1987, 41, 112–114.
[28]
Somjen, D.; Weisman, Y.; Kohen, F.; Gayer, B.; Limor, R.; Sharon, O.; Jaccard, N.; Knoll, E.; Stern, N. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005, 111, 1666–1671, doi:10.1161/01.CIR.0000160353.27927.70.
[29]
Wu-Wong, J.R. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br. J. Pharmacol. 2009, 158, 395–412, doi:10.1111/j.1476-5381.2009.00171.x.
[30]
Zittermann, A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog. Biophys. Mol. Biol. 2006, 92, 39–48, doi:10.1016/j.pbiomolbio.2006.02.001.
[31]
Hagenau, T.; Vest, R.; Gissel, T.N.; Poulsen, C.S.; Erlandsen, M.; Mosekilde, L.; Vestergaard, P. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: An ecologic meta-regression analysis. Osteoporos. Int. 2009, 20, 133–140, doi:10.1007/s00198-008-0626-y.
[32]
Ginde, A.A.; Liu, M.C.; Camargo, C.A., Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch. Intern. Med. 2009, 169, 626–632, doi:10.1001/archinternmed.2008.604.
[33]
Godar, D.E.; Landry, R.J.; Lucas, A.D. Increased uva exposures and decreased cutaneous vitamin D3 levels may be responsible for the increasing incidence of melanoma. Med. Hypotheses 2009, 72, 434–443, doi:10.1016/j.mehy.2008.09.056.
[34]
Zittermann, A.; Schleithoff, S.S.; Koerfer, R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br. J. Nutr. 2005, 94, 483–492, doi:10.1079/BJN20051544.
[35]
Tangpricha, V.; Koutkia, P.; Rieke, S.M.; Chen, T.C.; Perez, A.A.; Holick, M.F. Fortification of orange juice with vitamin D: A novel approach for enhancing vitamin D nutritional health. Am. J. Clin. Nutr. 2003, 77, 1478–1483.
[36]
Holick, M.F.; Biancuzzo, R.M.; Chen, T.C.; Klein, E.K.; Young, A.; Bibuld, D.; Reitz, R.; Salameh, W.; Ameri, A.; Tannenbaum, A.D. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrinol. Metab. 2008, 93, 677–681.
[37]
Bacon, C.J. High-Dose Vitamin D Supplementation in the Elderly. In Handbook of Vitamin D in Human Health; Watson, R.R., Ed.; Wageningen Academic Publishers: Wageningen, the Netherlands, 2013.
[38]
Melamed, M.L.; Michos, E.D.; Post, W.; Astor, B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 2008, 168, 1629–1637, doi:10.1001/archinte.168.15.1629.
[39]
Cannell, J.J.; Hollis, B.W. Use of vitamin D in clinical practice. Altern. Med. Rev. 2008, 13, 6–20.
[40]
Bischoff-Ferrari, H.A.; Giovannucci, E.; Willett, W.C.; Dietrich, T.; Dawson-Hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006, 84, 18–28.
[41]
Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930, doi:10.1210/jc.2011-0385.
[42]
Li, Y.C.; Kong, J.; Wei, M.; Chen, Z.F.; Liu, S.Q.; Cao, L.P. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Investig. 2002, 110, 229–238.
[43]
Pilz, S.; Tomaschitz, A.; Ritz, E.; Pieber, T.R. Vitamin D status and arterial hypertension: A systematic review. Nat. Rev. Cardiol. 2009, 6, 621–630, doi:10.1038/nrcardio.2009.135.
[44]
Rammos, G.; Tseke, P.; Ziakka, S. Vitamin D, the renin-angiotensin system, and insulin resistance. Int. Urol. Nephrol. 2008, 40, 419–426, doi:10.1007/s11255-007-9244-4.
[45]
Scragg, R.; Sowers, M.; Bell, C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. Am. J. Hypertens. 2007, 20, 713–719, doi:10.1016/j.amjhyper.2007.01.017.
[46]
Judd, S.E.; Nanes, M.S.; Ziegler, T.R.; Wilson, P.W.; Tangpricha, V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white americans: Results from the third national health and nutrition examination survey. Am. J. Clin. Nutr. 2008, 87, 136–141.
[47]
Martins, D.; Wolf, M.; Pan, D.; Zadshir, A.; Tareen, N.; Thadhani, R.; Felsenfeld, A.; Levine, B.; Mehrotra, R.; Norris, K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the united states: Data from the third national health and nutrition examination survey. Arch. Intern. Med. 2007, 167, 1159–1165, doi:10.1001/archinte.167.11.1159.
[48]
Hintzpeter, B.; Mensink, G.B.; Thierfelder, W.; Muller, M.J.; Scheidt-Nave, C. Vitamin D status and health correlates among german adults. Eur. J. Clin. Nutr. 2008, 62, 1079–1089, doi:10.1038/sj.ejcn.1602825.
[49]
Hypponen, E.; Boucher, B.J.; Berry, D.J.; Power, C. 25-hydroxyvitamin d, igf-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 british birth cohort. Diabetes 2008, 57, 298–305.
[50]
Forouhi, N.G.; Luan, J.; Cooper, A.; Boucher, B.J.; Wareham, N.J. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: The medical research council ely prospective study 1990–2000. Diabetes 2008, 57, 2619–2625, doi:10.2337/db08-0593.
[51]
Reis, J.P.; von Muhlen, D.; Kritz-Silverstein, D.; Wingard, D.L.; Barrett-Connor, E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007, 30, 1549–1555, doi:10.2337/dc06-2438.
[52]
Gannage-Yared, M.H.; Chedid, R.; Khalife, S.; Azzi, E.; Zoghbi, F.; Halaby, G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur. J. Endocrinol. 2009, 160, 965–971, doi:10.1530/EJE-08-0952.
[53]
Pasco, J.A.; Henry, M.J.; Nicholson, G.C.; Brennan, S.L.; Kotowicz, M.A. Behavioural and physical characteristics associated with vitamin D status in women. Bone 2009, 44, 1085–1091.
[54]
Rueda, S.; Fernandez-Fernandez, C.; Romero, F.; Martinez de Osaba, J.; Vidal, J. Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. Obes. Surg. 2008, 18, 151–154, doi:10.1007/s11695-007-9352-3.
[55]
Chan, R.; Chan, D.; Woo, J.; Ohlsson, C.; Mellstrom, D.; Kwok, T.; Leung, P. Serum 25-hydroxyvitamin D and parathyroid hormone levels in relation to blood pressure in a cross-sectional study in older chinese men. J. Hum. Hypertens. 2012, 26, 20–27, doi:10.1038/jhh.2010.126.
[56]
Williams, D.M.; Fraser, A.; Lawlor, D.A. Associations of vitamin D, parathyroid hormone and calcium with cardiovascular risk factors in US adolescents. Heart 2011, 97, 315–320, doi:10.1136/hrt.2010.203224.
[57]
Dorjgochoo, T.; Shu, X.O.; Xiang, Y.B.; Yang, G.; Cai, Q.; Li, H.; Ji, B.T.; Cai, H.; Gao, Y.T.; Zheng, W. Circulating 25-hydroxyvitamin D levels in relation to blood pressure parameters and hypertension in the shanghai women’s and men’s health studies. Br. J. Nutr. 2012, 108, 449–458, doi:10.1017/S0007114511005745.
[58]
Snijder, M.B.; Lips, P.; Seidell, J.C.; Visser, M.; Deeg, D.J.; Dekker, J.M.; van Dam, R.M. Vitamin D status and parathyroid hormone levels in relation to blood pressure: A population-based study in older men and women. J. Intern. Med. 2007, 261, 558–565, doi:10.1111/j.1365-2796.2007.01778.x.
[59]
Bolland, M.J.; Bacon, C.J.; Horne, A.M.; Mason, B.H.; Ames, R.W.; Wang, T.K.; Grey, A.B.; Gamble, G.D.; Reid, I.R. Vitamin D insufficiency and health outcomes over 5 year in older women. Am. J. Clin. Nutr. 2010, 91, 82–89, doi:10.3945/ajcn.2009.28424.
[60]
Margolis, K.L.; Martin, L.W.; Ray, R.M.; Kerby, T.J.; Allison, M.A.; Curb, J.D.; Kotchen, T.A.; Liu, S.; Wassertheil-Smoller, S.; Manson, J.E. A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women. Am. J. Epidemiol. 2012, 175, 22–32, doi:10.1093/aje/kwr274.
[61]
Wang, T.J.; Pencina, M.J.; Booth, S.L.; Jacques, P.F.; Ingelsson, E.; Lanier, K.; Benjamin, E.J.; D’Agostino, R.B.; Wolf, M.; Vasan, R.S. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117, 503–511, doi:10.1161/CIRCULATIONAHA.107.706127.
[62]
Forman, J.P.; Giovannucci, E.; Holmes, M.D.; Bischoff-Ferrari, H.A.; Tworoger, S.S.; Willett, W.C.; Curhan, G.C. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49, 1063–1069, doi:10.1161/HYPERTENSIONAHA.107.087288.
[63]
Margolis, K.L.; Ray, R.M.; van Horn, L.; Manson, J.E.; Allison, M.A.; Black, H.R.; Beresford, S.A.; Connelly, S.A.; Curb, J.D.; Grimm, R.H., Jr.; et al. Effect of calcium and vitamin D supplementation on blood pressure: The women’s health initiative randomized trial. Hypertension 2008, 52, 847–855, doi:10.1161/HYPERTENSIONAHA.108.114991.
[64]
Wood, A.D.; Secombes, K.R.; Thies, F.; Aucott, L.; Black, A.J.; Mavroeidi, A.; Simpson, W.G.; Fraser, W.D.; Reid, D.M.; Macdonald, H.M. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: A parallel-group, double-blind, placebo-controlled RCT. J. Clin. Endocrinol. Metab. 2012, 97, 3557–3568, doi:10.1210/jc.2012-2126.
[65]
Pfeifer, M.; Begerow, B.; Minne, H.W.; Nachtigall, D.; Hansen, C. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 2001, 86, 1633–1637, doi:10.1210/jc.86.4.1633.
[66]
Sugden, J.A.; Davies, J.I.; Witham, M.D.; Morris, A.D.; Struthers, A.D. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 2008, 25, 320–325, doi:10.1111/j.1464-5491.2007.02360.x.
[67]
Witham, M.D.; Nadir, M.A.; Struthers, A.D. Effect of vitamin d on blood pressure: A systematic review and meta-analysis. J. Hypertens. 2009, 27, 1948–1954, doi:10.1097/HJH.0b013e32832f075b.
[68]
Widlansky, M.E.; Gokce, N.; Keaney, J.F., Jr.; Vita, J.A. The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. 2003, 42, 1149–1160, doi:10.1016/S0735-1097(03)00994-X.
[69]
Nadar, S.; Blann, A.D.; Lip, G.Y. Endothelial dysfunction: Methods of assessment and application to hypertension. Curr. Pharm. Des. 2004, 10, 3591–3605, doi:10.2174/1381612043382765.
Norman, P.E.; Powell, J.T. Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 39–46.
[72]
Zehnder, D.; Bland, R.; Chana, R.S.; Wheeler, D.C.; Howie, A.J.; Williams, M.C.; Stewart, P.M.; Hewison, M. Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 2002, 13, 621–629.
[73]
Molinari, C.; Uberti, F.; Grossini, E.; Vacca, G.; Carda, S.; Invernizzi, M.; Cisari, C. 1α,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell. Physiol. Biochem. 2011, 27, 661–668, doi:10.1159/000330075.
[74]
Aihara, K.; Azuma, H.; Akaike, M.; Ikeda, Y.; Yamashita, M.; Sudo, T.; Hayashi, H.; Yamada, Y.; Endoh, F.; Fujimura, M.; et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 2004, 279, 35798–35802, doi:10.1074/jbc.M404865200.
[75]
Urena-Torres, P.; Metzger, M.; Haymann, J.P.; Karras, A.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Gauci, C.; Froissart, M.; Houillier, P.; et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am. J. Kidney Dis. 2011, 58, 544–553, doi:10.1053/j.ajkd.2011.04.029.
[76]
Tarcin, O.; Yavuz, D.G.; Ozben, B.; Telli, A.; Ogunc, A.V.; Yuksel, M.; Toprak, A.; Yazici, D.; Sancak, S.; Deyneli, O.; et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J. Clin. Endocrinol. Metab. 2009, 94, 4023–4030, doi:10.1210/jc.2008-1212.
[77]
Jablonski, K.L.; Chonchol, M.; Pierce, G.L.; Walker, A.E.; Seals, D.R. 25-hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011, 57, 63–69, doi:10.1161/HYPERTENSIONAHA.110.160929.
[78]
Pilz, S.; Tomaschitz, A.; Drechsler, C.; Ritz, E.; Boehm, B.O.; Grammer, T.B.; Marz, W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur. Heart J. 2010, 31, 1591–1598, doi:10.1093/eurheartj/ehq109.
[79]
Momiyama, Y.; Ohmori, R.; Tanaka, N.; Kato, R.; Taniguchi, H.; Adachi, T.; Nakamura, H.; Ohsuzu, F. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis 2010, 209, 206–210, doi:10.1016/j.atherosclerosis.2009.07.037.
[80]
Yiu, Y.F.; Chan, Y.H.; Yiu, K.H.; Siu, C.W.; Li, S.W.; Wong, L.Y.; Lee, S.W.L.; Tam, S.; Wong, E.W.K.; Cheung, B.M.Y.; et al. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2011, 96, E830–E835, doi:10.1210/jc.2010-2212.
[81]
Codoner-Franch, P.; Tavarez-Alonso, S.; Simo-Jorda, R.; Laporta-Martin, P.; Carratala-Calvo, A.; Alonso-Iglesias, E. Vitamin D status is linked to biomarkers of oxidative stress, inflammation, and endothelial activation in obese children. J. Pediatr. 2012, 161, 848–854, doi:10.1016/j.jpeds.2012.04.046.
[82]
Stricker, H.; Tosi Bianda, F.; Guidicelli-Nicolosi, S.; Limoni, C.; Colucci, G. Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in patients with peripheral arterial disease: A randomised controlled pilot study. Eur. J. Vasc. Endovasc. Surg. 2012, 44, 307–312.
[83]
Longenecker, C.T.; Hileman, C.O.; Carman, T.L.; Ross, A.C.; Seydafkan, S.; Brown, T.T.; Labbato, D.E.; Storer, N.; Tangpricha, V.; McComsey, G.A. Vitamin D supplementation and endothelial function in vitamin D deficient hiv-infected patients: A randomized placebo-controlled trial. Antivir. Ther. 2012, 17, 613–621.
[84]
Gepner, A.D.; Ramamurthy, R.; Krueger, D.C.; Korcarz, C.E.; Binkley, N.; Stein, J.H. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One 2012, 7, e36617.
[85]
Shab-Bidar, S.; Neyestani, T.R.; Djazayery, A.; Eshraghian, M.R.; Houshiarrad, A.; Gharavi, A.; Kalayi, A.; Shariatzadeh, N.; Zahedirad, M.; Khalaji, N.; et al. Regular consumption of vitamin D-fortified yogurt drink (doogh) improved endothelial biomarkers in subjects with type 2 diabetes: A randomized double-blind clinical trial. BMC Med. 2011, 9, 125, doi:10.1186/1741-7015-9-125.
[86]
Harris, R.A.; Pedersen-White, J.; Guo, D.H.; Stallmann-Jorgensen, I.S.; Keeton, D.; Huang, Y.; Shah, Y.; Zhu, H.; Dong, Y. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight african-american adults. Am. J. Hypertens. 2011, 24, 557–562, doi:10.1038/ajh.2011.12.
[87]
Dong, Y.; Stallmann-Jorgensen, I.S.; Pollock, N.K.; Harris, R.A.; Keeton, D.; Huang, Y.; Li, K.; Bassali, R.; Guo, D.H.; Thomas, J.; et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-Hydroxyvitamin D, adiposity, and arterial stiffness. J. Clin. Endocrinol. Metab. 2010, 95, 4584–4591, doi:10.1210/jc.2010-0606.
[88]
Witham, M.D.; Dove, F.J.; Sugden, J.A.; Doney, A.S.; Struthers, A.D. The effect of vitamin D replacement on markers of vascular health in stroke patients—A randomised controlled trial. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 864–870, doi:10.1016/j.numecd.2010.11.001.
[89]
Schleithoff, S.S.; Zittermann, A.; Tenderich, G.; Berthold, H.K.; Stehle, P.; Koerfer, R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2006, 83, 754–759.
[90]
Witham, M.D.; Dove, F.J.; Dryburgh, M.; Sugden, J.A.; Morris, A.D.; Struthers, A.D. The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: A randomised controlled trial. Diabetologia 2010, 53, 2112–2119, doi:10.1007/s00125-010-1838-1.
[91]
Al Mheid, I.; Patel, R.; Murrow, J.; Morris, A.; Rahman, A.; Fike, L.; Kavtaradze, N.; Uphoff, I.; Hooper, C.; Tangpricha, V.; et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J. Am. Coll. Cardiol. 2011, 58, 186–192.
[92]
Levin, A.; Bakris, G.L.; Molitch, M.; Smulders, M.; Tian, J.; Williams, L.A.; Andress, D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007, 71, 31–38, doi:10.1038/sj.ki.5002009.
[93]
Dusso, A.; Gonzalez, E.A.; Martin, K.J. Vitamin d in chronic kidney disease. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25, 647–655, doi:10.1016/j.beem.2011.05.005.
[94]
Moe, S.; Drueke, T.; Cunningham, J.; Goodman, W.; Martin, K.; Olgaard, K.; Ott, S.; Sprague, S.; Lameire, N.; Eknoyan, G. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (kdigo). Kidney Int. 2006, 69, 1945–1953, doi:10.1038/sj.ki.5000414.
[95]
Andress, D.L. Vitamin D in chronic kidney disease: A systemic role for selective vitamin d receptor activation. Kidney Int. 2006, 69, 33–43, doi:10.1038/sj.ki.5000045.
[96]
Jacob, A.I.; Sallman, A.; Santiz, Z.; Hollis, B.W. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 1984, 114, 1313–1319.
[97]
Barreto, D.V.; Barreto, F.C.; Liabeuf, S.; Temmar, M.; Boitte, F.; Choukroun, G.; Fournier, A.; Massy, Z.A. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 1128–1135, doi:10.2215/CJN.00260109.
[98]
Inaguma, D.; Nagaya, H.; Hara, K.; Tatematsu, M.; Shinjo, H.; Suzuki, S.; Mishima, T.; Kurata, K. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin. Exp. Nephrol. 2008, 12, 126–131, doi:10.1007/s10157-007-0023-4.
[99]
Ravani, P.; Malberti, F.; Tripepi, G.; Pecchini, P.; Cutrupi, S.; Pizzini, P.; Mallamaci, F.; Zoccali, C. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009, 75, 88–95, doi:10.1038/ki.2008.501.
[100]
De Boer, I.H.; Ioannou, G.N.; Kestenbaum, B.; Brunzell, J.D.; Weiss, N.S. 25-hydroxyvitamin D levels and albuminuria in the third national health and nutrition examination survey (NHANES iii). Am. J. Kidney Dis. 2007, 50, 69–77, doi:10.1053/j.ajkd.2007.04.015.
Shoben, A.B.; Rudser, K.D.; de Boer, I.H.; Young, B.; Kestenbaum, B. Association of oral calcitriol with improved survival in nondialyzed ckd. J. Am. Soc. Nephrol. 2008, 19, 1613–1619.
[103]
Wolf, M.; Shah, A.; Gutierrez, O.; Ankers, E.; Monroy, M.; Tamez, H.; Steele, D.; Chang, Y.; Camargo, C.A., Jr.; Tonelli, M.; et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007, 72, 1004–1013, doi:10.1038/sj.ki.5002451.
[104]
Mirkovic, K.; van den Born, J.; Navis, G.; de Borst, M.H. Vitamin D in chronic kidney disease: New potential for intervention. Curr. Drug Targets 2011, 12, 42–53, doi:10.2174/138945011793591572.
[105]
Li, Y.C. Vitamin D: Roles in renal and cardiovascular protection. Curr. Opin. Nephrol. Hypertens. 2012, 21, 72–79, doi:10.1097/MNH.0b013e32834de4ee.
[106]
Dusso, A.S.; Tokumoto, M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin d renoprotection: A downward spiral in kidney disease. Kidney Int. 2011, 79, 715–729, doi:10.1038/ki.2010.543.
[107]
Gal-Moscovici, A.; Sprague, S.M. Use of vitamin D in chronic kidney disease patients. Kidney Int. 2010, 78, 146–151, doi:10.1038/ki.2010.113.
[108]
Naves-Diaz, M.; Alvarez-Hernandez, D.; Passlick-Deetjen, J.; Guinsburg, A.; Marelli, C.; Rodriguez-Puyol, D.; Cannata-Andia, J.B. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008, 74, 1070–1078, doi:10.1038/ki.2008.343.
[109]
Teng, M.; Wolf, M.; Lowrie, E.; Ofsthun, N.; Lazarus, J.M.; Thadhani, R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003, 349, 446–456.
[110]
Teng, M.; Wolf, M.; Ofsthun, M.N.; Lazarus, J.M.; Hernan, M.A.; Camargo, C.A., Jr.; Thadhani, R. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J. Am. Soc. Nephrol. 2005, 16, 1115–1125.
[111]
De Zeeuw, D.; Agarwal, R.; Amdahl, M.; Audhya, P.; Coyne, D.; Garimella, T.; Parving, H.H.; Pritchett, Y.; Remuzzi, G.; Ritz, E.; et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (vital study): A randomised controlled trial. Lancet 2010, 376, 1543–1551, doi:10.1016/S0140-6736(10)61032-X.
[112]
Agarwal, R.; Acharya, M.; Tian, J.; Hippensteel, R.L.; Melnick, J.Z.; Qiu, P.; Williams, L.; Batlle, D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005, 68, 2823–2828, doi:10.1111/j.1523-1755.2005.00755.x.
[113]
Alborzi, P.; Patel, N.A.; Peterson, C.; Bills, J.E.; Bekele, D.M.; Bunaye, Z.; Light, R.P.; Agarwal, R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 2008, 52, 249–255, doi:10.1161/HYPERTENSIONAHA.108.113159.
[114]
Verstuyf, A.; Carmeliet, G.; Bouillon, R.; Mathieu, C. Vitamin D: A pleiotropic hormone. Kidney Int. 2010, 78, 140–145, doi:10.1038/ki.2010.17.
[115]
Jones, G. Expanding role for vitamin D in chronic kidney disease: Importance of blood 25-(OH)-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D3. Semin. Dial. 2007, 20, 316–324, doi:10.1111/j.1525-139X.2007.00302.x.
[116]
Hathcock, J.N.; Shao, A.; Vieth, R.; Heaney, R. Risk assessment for vitamin D. Am. J. Clin. Nutr. 2007, 85, 6–18.
[117]
Ozkan, B.; Hatun, S.; Bereket, A. Vitamin D intoxication. Turk. J. Pediatr. 2012, 54, 93–98.
[118]
Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.A.; Kotowicz, M.A.; Young, D.; Nicholson, G.C. Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA 2010, 303, 1815–1822, doi:10.1001/jama.2010.594.
[119]
Heaney, R.P. Vitamin D—Baseline status and effective dose. N. Engl. J. Med. 2012, 367, 77–78, doi:10.1056/NEJMe1206858.
[120]
Grey, A.; Bolland, M. Vitamin D: A place in the sun? Arch. Intern. Med. 2010, 170, 1099–1100, doi:10.1001/archinternmed.2010.174.
